FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379799707> ?p ?o ?g. }

• W4379799707 endingPage "e19" @default.
• W4379799707 startingPage "e18" @default.
• W4379799707 abstract "Objective: Data from randomized clinical trials showed that new-onset hypertension is a common side effect of anti-angiogenic drugs. We compared the cumulative incidence of new-onset hypertension in cancer patients treated with either anti-angiogenic based therapy (AAG) or other chemotherapy only, and in patients who did not received antineoplastic agents (untreated). Design and method: Retrospective population-based cohort study based on the healthcare utilization databases of Lombardy Region (Italy). We identified the cohort of patients aged 40 years or older with a new diagnosis of cancer between 2009 and 2017. We excluded patients with antihypertensive treatment in the five years before cancer diagnosis. We 1:1:1 matched each patient who started a therapy with AAG (index case) with one patient treated with other chemotherapy only and with one untreated patient by date of cancer diagnosis, tumoral site and date of start of antineoplastic therapy. We followed-up each of the three matched patients from the date of start of AAG of the index case until the first date between onset of antihypertensive treatment with at least 3 prescriptions (the outcome of interest), death, migration or 2 years after the start of follow-up. We estimated the incidence cumulative function by considering death as competing event and we fitted a Fine and Grey regression model, adjusted for age, sex and Cancer Multimorbidity Score, in order to estimate the association between treatment and new-onset hypertension. Results: The final cohort included 3,333 1:1:1 matched patients (median age 62 years; 43.6% males). The cumulative incidence of new-onset hypertension was higher among patients treated with AAG, as compared to others. The cumulative incidence rapidly increased 1 year (26.3%) after starting therapy with AAG. The adjusted hazard ratios were 3.73 (95% CI 3.34 to 4.15) and 4.00 (3.56 to 4.48), when compared to patients treated with other chemotherapy and with those untreated, respectively. Moreover, patients treated with AAG also showed a significant increased risk of major cardiovascular events compared to others. Conclusions: Cancer patients treated with AAG showed a markedly higher risk of new-onset hypertension. The risk rapidly increased 1 year after the start of therapy." @default.
• W4379799707 created "2023-06-09" @default.
• W4379799707 creator A5022257735 @default.
• W4379799707 creator A5045075334 @default.
• W4379799707 creator A5064813185 @default.
• W4379799707 creator A5084756058 @default.
• W4379799707 date "2023-06-01" @default.
• W4379799707 modified "2023-09-23" @default.
• W4379799707 title "HYPERTENSION IN CANCER PATIENTS TREATED WITH ANTI-ANGIOGENIC BASED THERAPY: A POPULATION-BASED COHORT STUDY" @default.
• W4379799707 doi "https://doi.org/10.1097/01.hjh.0000939060.54285.14" @default.
• W4379799707 hasPublicationYear "2023" @default.
• W4379799707 type Work @default.
• W4379799707 citedByCount "0" @default.
• W4379799707 crossrefType "journal-article" @default.
• W4379799707 hasAuthorship W4379799707A5022257735 @default.
• W4379799707 hasAuthorship W4379799707A5045075334 @default.
• W4379799707 hasAuthorship W4379799707A5064813185 @default.
• W4379799707 hasAuthorship W4379799707A5084756058 @default.
• W4379799707 hasBestOaLocation W43797997071 @default.
• W4379799707 hasConcept C120665830 @default.
• W4379799707 hasConcept C121332964 @default.
• W4379799707 hasConcept C121608353 @default.
• W4379799707 hasConcept C126322002 @default.
• W4379799707 hasConcept C141071460 @default.
• W4379799707 hasConcept C167135981 @default.
• W4379799707 hasConcept C187212893 @default.
• W4379799707 hasConcept C201903717 @default.
• W4379799707 hasConcept C2908647359 @default.
• W4379799707 hasConcept C61511704 @default.
• W4379799707 hasConcept C71924100 @default.
• W4379799707 hasConcept C72563966 @default.
• W4379799707 hasConcept C88879693 @default.
• W4379799707 hasConcept C99454951 @default.
• W4379799707 hasConceptScore W4379799707C120665830 @default.
• W4379799707 hasConceptScore W4379799707C121332964 @default.
• W4379799707 hasConceptScore W4379799707C121608353 @default.
• W4379799707 hasConceptScore W4379799707C126322002 @default.
• W4379799707 hasConceptScore W4379799707C141071460 @default.
• W4379799707 hasConceptScore W4379799707C167135981 @default.
• W4379799707 hasConceptScore W4379799707C187212893 @default.
• W4379799707 hasConceptScore W4379799707C201903717 @default.
• W4379799707 hasConceptScore W4379799707C2908647359 @default.
• W4379799707 hasConceptScore W4379799707C61511704 @default.
• W4379799707 hasConceptScore W4379799707C71924100 @default.
• W4379799707 hasConceptScore W4379799707C72563966 @default.
• W4379799707 hasConceptScore W4379799707C88879693 @default.
• W4379799707 hasConceptScore W4379799707C99454951 @default.
• W4379799707 hasIssue "Suppl 3" @default.
• W4379799707 hasLocation W43797997071 @default.
• W4379799707 hasOpenAccess W4379799707 @default.
• W4379799707 hasPrimaryLocation W43797997071 @default.
• W4379799707 hasRelatedWork W1967986271 @default.
• W4379799707 hasRelatedWork W2131385545 @default.
• W4379799707 hasRelatedWork W2142660571 @default.
• W4379799707 hasRelatedWork W2146312256 @default.
• W4379799707 hasRelatedWork W2147263480 @default.
• W4379799707 hasRelatedWork W2409957712 @default.
• W4379799707 hasRelatedWork W2559287584 @default.
• W4379799707 hasRelatedWork W2586280594 @default.
• W4379799707 hasRelatedWork W3172893480 @default.
• W4379799707 hasRelatedWork W99283317 @default.
• W4379799707 hasVolume "41" @default.
• W4379799707 isParatext "false" @default.
• W4379799707 isRetracted "false" @default.
• W4379799707 workType "article" @default.